ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2051

Risk Factors for Cardiovascular Disease Predate the Onset of Symptoms of Rheumatoid Arthritis

Heidi Kokkonen1, Lisbeth Ärlestig2 and Solbritt Rantapää-Dahlqvist3,4, 1Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, 2Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 3Department for Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, 4Rheumatology, Umeå University, Umeå, Sweden

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: body mass, Cardiovascular disease, hypertension, lipids and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Clinical Aspects III: Prevention of Comorbidity

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of developing cardiovascular (CV) comorbidity compared with the general population. Contradictory results concerning CV disease prior to onset of RA have been reported. Of the known CVD risk factors, a more atherogenic lipid profile and smoking have been presented prior to RA onset. In this study, lifestyle factors, lipid levels, presence of hypertension and diabetes were evaluated in individuals prior to onset of symptoms of RA and matched population controls from northern Sweden.

Methods: A nested case-control study was based on population surveys from The Västerbotten Intervention Programme (VIP) and the WHO Multinational Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA). Data were collected by a questionnaire (socioeconomic and lifestyle factors), assessments by a nurse (body mass index; BMI, waist and blood pressure), and blood sampling. The registers of patients with RA (ARA criteria) attending the Department of Rheumatology, Umeå was co-analysed with the registers from VIP and MONICA. This study included 547 pre-symptomatic individuals (median age 50.2 years; 372f/175m, median (IQR) predating time 5.0 (7.0) years), and 1641 controls (median age 50.3 years; 1116f/525m). CVD risk factors were defined as: hypertension (systolic ≥140 mmHg and/or diastolic ≥90 mmHg including hypertensive treatment), elevated ApoB/ApoA1 ratio (females ≥0.7, males ≥0.8, including lipid lowering treatment), BMI ≥25, diabetes, and ever smoker.

Results: In conditional logistic regression models elevated ApoB/ApoA1 ratio (OR 1.3 (95% CI 1.0,1.6)), smoking (OR 2.0 (95% CI 1.6,2.5)), BMI≥ 25 (OR 1.3 (95% CI 1.1,1.6)) and diabetes (OR 2.0 (95% CI 1.1,3.7)) were associated with individuals who subsequently developed RA. In women elevated ApoB/ApoA1 (OR 1.4 (95% CI 1.1-1.8)), smoking (OR 1.9 (95% CI 1.1-1.8)), and BMI ≥25 (OR 1.3 (95% CI 1.1-1.7)) were significant for being pre-symptomatic for RA, in men the risk factors were smoking (OR 2.2 (95% CI 1.5-2.5), and diabetes (OR 4.7 (95% CI 1.71-13.1)). Stratifying on the median age, the factor remaining significant for the future RA group in older individuals was smoking (OR 1.7 (95% CI 1.2,2.5)), whereas in the individuals ≤50.2 years the factors were: elevated ApoB/ApoA1 ratio (OR 1.4 (95% CI 1.0,1.9)), BMI ≥25.0 (OR 1.5 (95% CI 1.0-2.0)), and smoking (OR 2.1 (95% CI 1.5,3.0). The pre-symptomatic individuals had significantly higher frequency of risk factors, 42% had ≥3 of these compared with 30% of the matched controls (OR 2.8 (95% CI 1.8, 4.5)). Especially, ACPA positive pre-symptomatic individuals had a high OR for future RA when having ≥3 of the CV risk factors (OR 5.7 (95% CI 2.1-15.3)).

Conclusion: Several of the CV risk factors were present in individuals already years before onset of symptoms of RA. One third of the pre-symptomatic individuals had at least 3 of these factors present. The risk factors for CVD associated with future RA differ between women and men. In younger individuals as well as ACPA positive individuals the CVD risk factors have a greater impact. These results urge an early CV prevention in patients with RA.


Disclosure: H. Kokkonen, None; L. Ärlestig, None; S. Rantapää-Dahlqvist, None.

To cite this abstract in AMA style:

Kokkonen H, Ärlestig L, Rantapää-Dahlqvist S. Risk Factors for Cardiovascular Disease Predate the Onset of Symptoms of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/risk-factors-for-cardiovascular-disease-predate-the-onset-of-symptoms-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-for-cardiovascular-disease-predate-the-onset-of-symptoms-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology